- Home
- RMAX vs ATLN Comparison
RMAX vs ATLN Comparison
Compare RMAX & ATLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMAX
- ATLN
- Stock Information
- Founded
- RMAX 1973
- ATLN 2014
- Country
- RMAX United States
- ATLN United States
- Employees
- RMAX N/A
- ATLN N/A
- Industry
- RMAX Real Estate
- ATLN
- Sector
- RMAX Finance
- ATLN
- Exchange
- RMAX Nasdaq
- ATLN NYSE
- Market Cap
- RMAX 161.9M
- ATLN 137.6M
- IPO Year
- RMAX 2013
- ATLN 2021
- Fundamental
- Price
- RMAX $7.29
- ATLN $3.92
- Analyst Decision
- RMAX Hold
- ATLN
- Analyst Count
- RMAX 1
- ATLN 0
- Target Price
- RMAX $10.50
- ATLN N/A
- AVG Volume (30 Days)
- RMAX 151.0K
- ATLN 54.0K
- Earning Date
- RMAX 05-01-2025
- ATLN 01-01-0001
- Dividend Yield
- RMAX N/A
- ATLN N/A
- EPS Growth
- RMAX N/A
- ATLN N/A
- EPS
- RMAX 0.37
- ATLN N/A
- Revenue
- RMAX $307,685,000.00
- ATLN $442,609,814.00
- Revenue This Year
- RMAX N/A
- ATLN N/A
- Revenue Next Year
- RMAX $1.25
- ATLN N/A
- P/E Ratio
- RMAX $19.70
- ATLN N/A
- Revenue Growth
- RMAX N/A
- ATLN 10.27
- 52 Week Low
- RMAX $6.90
- ATLN $1.30
- 52 Week High
- RMAX $14.31
- ATLN $8.98
- Technical
- Relative Strength Index (RSI)
- RMAX 34.80
- ATLN N/A
- Support Level
- RMAX $7.22
- ATLN N/A
- Resistance Level
- RMAX $7.87
- ATLN N/A
- Average True Range (ATR)
- RMAX 0.44
- ATLN 0.00
- MACD
- RMAX -0.03
- ATLN 0.00
- Stochastic Oscillator
- RMAX 24.53
- ATLN 0.00
About RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.
About ATLN ATLANTIC INTERNATIONAL CORP
Atlantic International Corp formerly SeqLL Inc is a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property across multiple omics fields. The company leverages its expertise with the True Single Molecule Sequencing platform to empower scientists and researchers with improved genetic tools to greater understand the molecular mechanisms of disease that is essential to the continued development of new breakthroughs in genomic medicine, and that hopefully address the critical concerns involved with precision medicine.